Australian Life Scientist

SECTION

Inside the bacterial machine

Professor Trevor Lithgow is tinkering with the cogs of bacteria to understand how they, and their mitochondrial cousins, tick.

Top Stories

Biosceptre, University of Queensland to collaborate on cancer antibodies

Biosceptre and the University of Queensland’s AIBN research institute have teamed up to develop a production method for monoclonal antibodies designed to trigger cancer cell death.
Australian Synchrotron to use Bluechiip tracking tech

The Australian Synchrotron will use a new tracking technology developed by Bluechiip (ASX:BCT) to keep track of samples in extreme temperatures.
Gene patents challenged again

A Labor backbencher has brought the gene patent controversy to the fore once again with a private member’s bill to ban patents on genetic material.
Bioniche burn rate rises on animal health spend

Bioniche (ASX:BNC) revealed its burn rate increased in the March quarter as it stepped up efforts to improve its bottom line through increased animal health sales.
Alchemia gaining US share for anticoagulant

US sales of generic fondaparinux, the anticoagulant produced by Alchemia (ASX:ACL), are expected to have grown 120% year-on-year.
Feature: Inside the bacterial machine

Professor Trevor Lithgow is tinkering with the cogs of bacteria to understand how they, and their mitochondrial cousins, tick.
IPO-bound Ventus Medical eyes market growth

Ventus Medical plans to use the proceeds of its upcoming ASX IPO to fund efforts to build a market for its sleep disorder breathing products.
Phosphagenics lands retail deal with David Jones

Retail chain David Jones has agreed to stock the Elixia range of skincare products from Melbourne-based Phosphagenics (ASX:POH).
CathRx looks to delist from ASX

Cardiac catheter company CathRx (ASX:CXD) will likely seek shareholder approval to go private after it raises funds to pursue a potential sale of the company.
BioDiem, VIVALIS team for viral vector research

BioDiem (ASX:BDM) and France's VIVALIS are exploring the feasibility of using BioDiem's LAIV flu virus to create a viral vector for non-influenza vaccines.
Science and biotech survive surplus budget

Despite a budget riddled with cuts, funding for science has increased and the recently-passed R&D Tax Incentive has remained intact.
Flu license fees nothing to sneeze at for BioDiem

BioDiem (ASX:BDM) has received license fees totalling around 10% of its market cap from its LAIV flu vaccine technology.
Hydrix wins Victorian enabling technology award

Hydrix, an engineering consultancy company operating in the medical device and other sectors, has won an award from the Victorian Manufacturing Hall of Fame.
Movers and shakers

TGA national manager; Hatchtech's new CEO; Starpharma’s new director; Immuron CEO; University of Queensland vice chancellor and president.
Immuron taps NZ dairy for colostrum production

Immuron (ASX:IMC) has signed a deal with dairy processing company Synlait covering the production of colostrum needed for its Travelan drug.
IQnovate to commercialise Nanosonics’ disinfection system

Contract medical company IQnovate (ASX:IQN) has signed an MoU with Sydney's Nanosonics to help commercialise an ultrasound disinfection system.